Clinical Trial Update: A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial followed by open-label extension evaluating long-term safety and efficacy of ianalumab in Sjogren's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogrens Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING